Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Survodutide - Boehringer Ingelheim

Next Previous
Drug Profile

Survodutide - Boehringer Ingelheim

Alternative Names: BI-456906; BI-456909

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zealand Pharma
  • Developer Boehringer Ingelheim; Zealand Pharma
  • Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity; Type 2 diabetes mellitus
  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Apr 2024 Boehringer Ingelheim plans to initiate a phase I trial for Obesity (Monotherapy, In combination therapy) (SC) (NCT06352424)
  • 03 Apr 2024 Boehringer Ingelheim plans a phase I trial in Renal impairment (Treatment-experienced) (SC, Injection) in May 2024 (NCT06352411)
  • 13 Mar 2024 Boehringer Ingelheim plans a phase III trial for Obesity and Non-Alcoholic Steatohepatitis in March 2024 (SC) (NCT06309992 )
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top